Effect of budesonide and azelastine on histamine signaling regulation in human nasal epithelial cells

Shao Cheng Liu, Chun Shu Lin, Shyi Gen Chen, Yueng Hsiang Chu, Fei Peng Lee, Hsuan Hsuan Lu, Hsing Won Wang

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Both glucocorticoids and H1-antihistamines are widely used on patients with airway diseases. However, their direct effects on airway epithelial cells are not fully explored. Therefore, we use the primary culture of human nasal epithelial cells (HNEpC) to delineate in vitro mucosal responses to above two drugs. HNEpC cells were cultured with/without budesonide and azelastine. The growth rate at each group was recorded and measured as population double time (PDT). The histamine1-receptor (H1R), muscarinic1-receptor (M1R) and M3R were measured using immunocytochemistry and western blotting after 7-days treatment. Then, we used histamine and methacholine to stimulate the mucus secretion from HNEpC and observed the MUC5AC expression in culture supernatants. Concentration-dependent treatment-induced inhibition of HNEpC growth rate was observed. Cells incubated with azelastine proliferated significantly slower than that with budesonide and the combined use of those drugs led to significant PDT prolong. The immunocytochemistry showed the H1R, M1R and M3R were obviously located in the cell membrane without apparent difference after treatment. However, western blotting showed that budesonide can significantly up-regulate the H1R, M1R and M3R level while azelastine had opposite effects. Histamine and methacholine stimulated MUC5AC secretion was greater in cells treated with budesonide but was lesser in those treated with azelastine, as compared to controls. Our data suggest that both budesonide and azelastine can significantly inhibit HNEpC proliferation, and therefore, be helpful in against airway remodeling. Long-term use of budesonide might amplify histamine signaling and result in airway hyperreactivity to stimulants by enhancing H1R, M1R and M3R expression while azelastine can oppose this effect. Therefore, combined use of those two drugs in patients with chronic inflammatory airway diseases may be an ideal option.

Original languageEnglish
Pages (from-to)845-853
Number of pages9
JournalEuropean Archives of Oto-Rhino-Laryngology
Volume274
Issue number2
DOIs
Publication statusPublished - Feb 1 2017

Fingerprint

azelastine
Budesonide
Nose
Histamine
Epithelial Cells
Methacholine Chloride
Western Blotting
Immunohistochemistry
Pharmaceutical Preparations
Airway Remodeling
Histamine Antagonists
Mucus
Growth
Glucocorticoids
Population
Cultured Cells
Up-Regulation
Therapeutics
Cell Proliferation
Cell Membrane

Keywords

  • Airway remodeling
  • Antihistamine
  • Glucocorticoid
  • Histamine receptor
  • Muscarinic receptor

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Effect of budesonide and azelastine on histamine signaling regulation in human nasal epithelial cells. / Liu, Shao Cheng; Lin, Chun Shu; Chen, Shyi Gen; Chu, Yueng Hsiang; Lee, Fei Peng; Lu, Hsuan Hsuan; Wang, Hsing Won.

In: European Archives of Oto-Rhino-Laryngology, Vol. 274, No. 2, 01.02.2017, p. 845-853.

Research output: Contribution to journalArticle

Liu, Shao Cheng ; Lin, Chun Shu ; Chen, Shyi Gen ; Chu, Yueng Hsiang ; Lee, Fei Peng ; Lu, Hsuan Hsuan ; Wang, Hsing Won. / Effect of budesonide and azelastine on histamine signaling regulation in human nasal epithelial cells. In: European Archives of Oto-Rhino-Laryngology. 2017 ; Vol. 274, No. 2. pp. 845-853.
@article{3910969c58c84b27aca60e6d8ad18945,
title = "Effect of budesonide and azelastine on histamine signaling regulation in human nasal epithelial cells",
abstract = "Both glucocorticoids and H1-antihistamines are widely used on patients with airway diseases. However, their direct effects on airway epithelial cells are not fully explored. Therefore, we use the primary culture of human nasal epithelial cells (HNEpC) to delineate in vitro mucosal responses to above two drugs. HNEpC cells were cultured with/without budesonide and azelastine. The growth rate at each group was recorded and measured as population double time (PDT). The histamine1-receptor (H1R), muscarinic1-receptor (M1R) and M3R were measured using immunocytochemistry and western blotting after 7-days treatment. Then, we used histamine and methacholine to stimulate the mucus secretion from HNEpC and observed the MUC5AC expression in culture supernatants. Concentration-dependent treatment-induced inhibition of HNEpC growth rate was observed. Cells incubated with azelastine proliferated significantly slower than that with budesonide and the combined use of those drugs led to significant PDT prolong. The immunocytochemistry showed the H1R, M1R and M3R were obviously located in the cell membrane without apparent difference after treatment. However, western blotting showed that budesonide can significantly up-regulate the H1R, M1R and M3R level while azelastine had opposite effects. Histamine and methacholine stimulated MUC5AC secretion was greater in cells treated with budesonide but was lesser in those treated with azelastine, as compared to controls. Our data suggest that both budesonide and azelastine can significantly inhibit HNEpC proliferation, and therefore, be helpful in against airway remodeling. Long-term use of budesonide might amplify histamine signaling and result in airway hyperreactivity to stimulants by enhancing H1R, M1R and M3R expression while azelastine can oppose this effect. Therefore, combined use of those two drugs in patients with chronic inflammatory airway diseases may be an ideal option.",
keywords = "Airway remodeling, Antihistamine, Glucocorticoid, Histamine receptor, Muscarinic receptor",
author = "Liu, {Shao Cheng} and Lin, {Chun Shu} and Chen, {Shyi Gen} and Chu, {Yueng Hsiang} and Lee, {Fei Peng} and Lu, {Hsuan Hsuan} and Wang, {Hsing Won}",
year = "2017",
month = "2",
day = "1",
doi = "10.1007/s00405-016-4295-8",
language = "English",
volume = "274",
pages = "845--853",
journal = "European Archives of Oto-Rhino-Laryngology",
issn = "0937-4477",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Effect of budesonide and azelastine on histamine signaling regulation in human nasal epithelial cells

AU - Liu, Shao Cheng

AU - Lin, Chun Shu

AU - Chen, Shyi Gen

AU - Chu, Yueng Hsiang

AU - Lee, Fei Peng

AU - Lu, Hsuan Hsuan

AU - Wang, Hsing Won

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Both glucocorticoids and H1-antihistamines are widely used on patients with airway diseases. However, their direct effects on airway epithelial cells are not fully explored. Therefore, we use the primary culture of human nasal epithelial cells (HNEpC) to delineate in vitro mucosal responses to above two drugs. HNEpC cells were cultured with/without budesonide and azelastine. The growth rate at each group was recorded and measured as population double time (PDT). The histamine1-receptor (H1R), muscarinic1-receptor (M1R) and M3R were measured using immunocytochemistry and western blotting after 7-days treatment. Then, we used histamine and methacholine to stimulate the mucus secretion from HNEpC and observed the MUC5AC expression in culture supernatants. Concentration-dependent treatment-induced inhibition of HNEpC growth rate was observed. Cells incubated with azelastine proliferated significantly slower than that with budesonide and the combined use of those drugs led to significant PDT prolong. The immunocytochemistry showed the H1R, M1R and M3R were obviously located in the cell membrane without apparent difference after treatment. However, western blotting showed that budesonide can significantly up-regulate the H1R, M1R and M3R level while azelastine had opposite effects. Histamine and methacholine stimulated MUC5AC secretion was greater in cells treated with budesonide but was lesser in those treated with azelastine, as compared to controls. Our data suggest that both budesonide and azelastine can significantly inhibit HNEpC proliferation, and therefore, be helpful in against airway remodeling. Long-term use of budesonide might amplify histamine signaling and result in airway hyperreactivity to stimulants by enhancing H1R, M1R and M3R expression while azelastine can oppose this effect. Therefore, combined use of those two drugs in patients with chronic inflammatory airway diseases may be an ideal option.

AB - Both glucocorticoids and H1-antihistamines are widely used on patients with airway diseases. However, their direct effects on airway epithelial cells are not fully explored. Therefore, we use the primary culture of human nasal epithelial cells (HNEpC) to delineate in vitro mucosal responses to above two drugs. HNEpC cells were cultured with/without budesonide and azelastine. The growth rate at each group was recorded and measured as population double time (PDT). The histamine1-receptor (H1R), muscarinic1-receptor (M1R) and M3R were measured using immunocytochemistry and western blotting after 7-days treatment. Then, we used histamine and methacholine to stimulate the mucus secretion from HNEpC and observed the MUC5AC expression in culture supernatants. Concentration-dependent treatment-induced inhibition of HNEpC growth rate was observed. Cells incubated with azelastine proliferated significantly slower than that with budesonide and the combined use of those drugs led to significant PDT prolong. The immunocytochemistry showed the H1R, M1R and M3R were obviously located in the cell membrane without apparent difference after treatment. However, western blotting showed that budesonide can significantly up-regulate the H1R, M1R and M3R level while azelastine had opposite effects. Histamine and methacholine stimulated MUC5AC secretion was greater in cells treated with budesonide but was lesser in those treated with azelastine, as compared to controls. Our data suggest that both budesonide and azelastine can significantly inhibit HNEpC proliferation, and therefore, be helpful in against airway remodeling. Long-term use of budesonide might amplify histamine signaling and result in airway hyperreactivity to stimulants by enhancing H1R, M1R and M3R expression while azelastine can oppose this effect. Therefore, combined use of those two drugs in patients with chronic inflammatory airway diseases may be an ideal option.

KW - Airway remodeling

KW - Antihistamine

KW - Glucocorticoid

KW - Histamine receptor

KW - Muscarinic receptor

UR - http://www.scopus.com/inward/record.url?scp=84987622614&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84987622614&partnerID=8YFLogxK

U2 - 10.1007/s00405-016-4295-8

DO - 10.1007/s00405-016-4295-8

M3 - Article

VL - 274

SP - 845

EP - 853

JO - European Archives of Oto-Rhino-Laryngology

JF - European Archives of Oto-Rhino-Laryngology

SN - 0937-4477

IS - 2

ER -